Assessment of proliferative activity, DNA values and some clinicopathologic parameters in mesenchymal tumors. Immunohistochemical and flow cytometric study.
Clinicopathologic parameters of 70 consecutive mesenchymal tumors from 63 patients were evaluated. In all these cases, the DNA content was analyzed by flow cytometry, and the expression of proliferative antigen MIB1 and p53 protein was assessed by immunohistochemistry. Our study verified the prognostic usefulness of proliferative indicators, above all MIB1-index, which strongly correlated with tumor grade and independently influenced overall survival.
Niezabitowski
A
A
Department of Tumor Pathology, Oncology Center, Cracow, Poland.
Ryś
J
J
Roessner
A
A
Lackowska
B
B
Schneider-Stock
R
R
Gruchała
A
A
Wasilewska
A
A
Kruczak
A
A
Swiatkiewicz
I
I
Sokolowski
A
A
Szklarski
W
W
Jaszcz
A
A
Stelmach
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D034961:Antigens, Nuclear; D015415:Biomarkers / Q000032:analysis; D001859:Bone Neoplasms / Q000378:metabolism* / Q000628:therapy; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000378:metabolism*; D011003:Ploidies; D012509:Sarcoma / Q000378:metabolism* / Q000628:therapy; D012983:Soft Tissue Neoplasms / Q000378:metabolism* / Q000628:therapy; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
D034961:Antigens, Nuclear; D015415:Biomarkers; D009687:Nuclear Proteins; D016159:Tumor Suppressor Protein p53